ROSACEA SUBTYPE 1 (ERYTHEMATOTELANGIECTATIC)

Clinical trials for ROSACEA SUBTYPE 1 (ERYTHEMATOTELANGIECTATIC) explained in plain language.

Never miss a new study

Get alerted when new ROSACEA SUBTYPE 1 (ERYTHEMATOTELANGIECTATIC) trials appear

Sign up with your email to follow new studies for ROSACEA SUBTYPE 1 (ERYTHEMATOTELANGIECTATIC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1 Completed 2

New cream aims to calm rosacea redness, with or without laser

Symptom relief Not yet recruiting

This study tests whether a dermocosmetic cream can reduce facial redness and visible blood vessels in people with a type of rosacea. Fifty adults will apply the cream or a placebo to different sides of their face twice daily for two months, then continue while also receiving lase…

Matched conditions: ROSACEA SUBTYPE 1 (ERYTHEMATOTELANGIECTATIC)

Phase: NA • Sponsor: ISISPHARMA • Aim: Symptom relief

Last updated May 15, 2026 11:55 UTC

ROSACEA SUBTYPE 1 (ERYTHEMATOTELANGIECTATIC)

Get alerted when new ROSACEA SUBTYPE 1 (ERYTHEMATOTELANGIECTATIC) trials appear

New cream aims to calm rosacea redness, with or without laser